Advertisement

Picture Kentro Design Corporate and Web Design for Start Ups 650x80px
Organisation › Details

MaxiVax S.A.

MaxiVAX is a private Swiss clinical-stage biotech company with a novel, patient-specific and personalized active immunotherapy treatment for cancer. The company received the 2017 CTI Swiss Medtech Award for its groundbreaking work, and its lead product MVX-ONCO-1, which is in Phase 2 development for Head & Neck cancer in Switzerland. The company successfully filed an IND with the US FDA in 2018. *

 

Period Start 2005-12-20 established
Products Industry cancer immunotherapy (immuno-oncology, I-O)
  Industry 2 MVX-ONCO-1 (MaxiVax)
Person Person Goundis, Dimitri (MaxiVax 201602– CEO before Acrongenomics + Speedel + Medicines Co Inc + Roche)
     
Region Region Genève (Geneva) GE
  Country Switzerland
  Street 24 rue de l’Athénée
  City 1206 Genève GE
  Tel +41-22-552-2613
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: MaxiVax S.A.. (9/25/18). "Press Release: MaxiVax Starts Phase 2 Study in Switzerland of Innovative Cancer Vaccine in Patients with Head & Neck Cancer". Geneva.
     
   
Record changed: 2019-11-27

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for MaxiVax S.A.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group ChinaBio Partnerting Forum 2021 651x80




» top